| 영문 | iron deficiency anemia | 한글 | 철결핍빈혈 |
|---|---|---|---|
| 설명 | 적혈구의 기능은 산소를 운반하는데 있다. 적혈구 속에 산소와 결합을 하여 산소를 운반하는 혈색소라는 물질이 있다. 철은 이 혈색소의 중요한 부분을 이루는 것으로 철이 없으면 혈색소가 만들어질 수가 없다. 혈색소가 없으면 역시 적혈구도 만들어지지 않으므로 체내에 철이 부족하면 빈혈이 생긴다. 이 철결핍성 빈혈은 빈혈의 원인 중에서 가장 흔한 것이다(약 25%를 차지한다). 철저장량의 저하-결핍, 혈청철농도의 저하, 트란스페린량 상승, 트란스페린포화도의 저하, 혈색소농도 또는 헤마토크리트의 저하, 저색소성대적혈구를 특징으로 하는 빈혈로서, 생체 내에서 철이 장기에 걸쳐 결핍되며 그 때문에 혈색소 생산 감소에 의해 일어난다. 창자에서의 철흡수량 부족, 철의 수요 증대(유아기, 사춘기, 임신), 철소실과잉(출혈)에 의해 일어나며, 특히 사춘기에서 폐경기까지의 여성에게 많다. 증상으로서는 얼굴창백, 피로감, 피부창백, 손톱 변화(스푼 모양) 등을 나타낸다. 구강 영역에서는 혀의 접촉통, 발적, 건조감, 삼킴곤란을 수반하면 플러머-빈슨(Plummer-Vinson)증후군이라고 한다. 혈액 소견은 혈청철은 저하하며, 철결합능력의 상승, 저색소성 작은적혈구성을 나타낸다. |
||
| MD | Doctor of Medicine [Lat. Medicinae Doctor]; magnesium deficiency; main duct; maintenance dose; major... |
|---|---|
| HCG, hCG | Human Chorionic Gonadotropin; 사람융모성성선자극호르몬 1. Placental Glycoprotein Hormone &nbs... |
| ICU | infant care unit; immunologic contact urticaria; intensive care unit; intermediate care unit |
| OILD | occupational immunologic lung disease |
| IGD | idiopathic growth hormone deficiency; interglobal distance; isolated gonadotropin deficiency |
| ATD | 1-antitrypsin deficiency |
|---|---|
| AMD | Acid maltase deficiency |
| AIDS | Acquire Immune Deficiency Syndrome |
| AIDS | Acquired Immune Deficiency Disease Syndrome |
| alpha1ATD | Alpha-1-antitrypsin deficiency |
| immunologic deficiency syndromes | Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. (12 Dec 1998) |
|---|
| adjuvants, immunologic | Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (freund's adjuvant, bcg, corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (12 Dec 1998) |
|---|---|
| receptors, immunologic | Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behaviour of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. (12 Dec 1998) |
| graft enhancement, immunologic | The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (12 Dec 1998) |
| monitoring, immunologic | Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumour antigen and other markers (often by radioimmunoassay), studies of cellular or humoral immunity in cancer aetiology, immunotherapy trials, etc. (12 Dec 1998) |
| contraception, immunologic | Contraceptive methods utilizing immunologic processes. (12 Dec 1998) |
| cytotoxicity, immunologic | The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitised T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. (12 Dec 1998) |
| cytotoxicity tests, immunologic | The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitised lymphocyte, an antibody, or complement. (12 Dec 1998) |
| suppressor factors, immunologic | Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-j) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory. (12 Dec 1998) |
| desensitization, immunologic | Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IgG, suppression of specific IgE, and an increase in suppressor T-cell activity. (12 Dec 1998) |
| dose-response relationship, immunologic | A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. (12 Dec 1998) |
| immunologic | <immunology> Pertaining to immunology. (18 Nov 1997) |
| immunologic and biological factors | A collective grouping for biologically active substances that play a role in the functioning of the immune system and those that show biological or physiological activity. (12 Dec 1998) |
| immunologic capping | The process by which lymphoid cell surface immunoglobulin receptors, when exposed to bivalent anti-ig antibodies, collect in patches and form a cap at one pole of the cell. The caps may then be endocytosed or shed into the environment in the form of antigen-antibody complexes. Capping has also been induced by lectins and antigens. (12 Dec 1998) |
| immunologic diseases | Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated or both. (12 Dec 1998) |
| immunologic factors | Biologically active substances whose activities affect or play a role in the functioning of the immune system. (12 Dec 1998) |
Synonyms : Deficiency Syndrome, Immunologic, Deficiency Syndromes, Antibody, Deficiency Syndromes, Immunologic, Immunologic Deficiency Syndrome, Immunological Deficiency Syndromes, Antibody Deficiency Syndromes, Deficiency Syndrome, Antibody
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|